|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lee WS, Yun SH, Chun HK, Lee WY, Yun HR,
Kim J, Kim K and Shim YM: Pulmonary resection for metastases from
colorectal cancer: Prognostic factors and survival. Int J
Colorectal Dis. 22:699–704. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yoo PS, Lopez-Soler RI, Longo WE and Cha
CH: Liver resection for metastatic colorectal cancer in the age of
neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer.
6:202–207. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mowaka S, Ziehe M, Mohamed D, Hochkirch U,
Thomale J and Linscheid MW: Structures of
oxaliplatin-oligonucleotide adducts from DNA. J Mass Spectrom.
47:1282–1293. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Virag P, Perde-Schrepler M, Fischer-Fodor
E, Tatomir C, Dorneanu SA, Cernea VI and Irimie A: Superior
cytotoxicity and DNA cross-link induction by oxaliplatin versus
cisplatin at lower cellular uptake in colorectal cancer cell lines.
Anticancer Drugs. 23:1032–1038. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Saltz LB, Clarke S, Diaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Bevacizumab in combination with oxaliplatin-based
chemotherapy as first-line therapy in metastatic colorectal cancer:
A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Douillard JY, Siena S, Cassidy J,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Randomized, phase III trial of panitumumab with
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)
versus FOLFOX4 alone as first-line treatment in patients with
previously untreated metastatic colorectal cancer: The PRIME study.
J Clin Oncol. 28:4697–4705. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bokemeyer C, Bondarenko I, Makhson A,
Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G,
Stroh C, et al: Fluorouracil, leucovorin, and oxaliplatin with and
without cetuximab in the first-line treatment of metastatic
colorectal cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zheng N, Schulman BA, Song L, Miller JJ,
Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, et al:
Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase
complex. Nature. 416:703–709. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soucy TA, Smith PG, Milhollen MA, Berger
AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP,
Critchley S, et al: An inhibitor of NEDD8-activating enzyme as a
new approach to treat cancer. Nature. 458:732–736. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Petroski MD and Deshaies RJ: Function and
regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol.
6:9–20. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Petroski MD: Mechanism-based neddylation
inhibitor. Chem Biol. 17:6–8. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Soucy TA, Dick LR, Smith PG, Milhollen MA
and Brownell JE: The NEDD8 conjugation pathway and its relevance in
cancer biology and therapy. Genes Cancer. 1:708–716. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brownell JE, Sintchak MD, Gavin JM, Liao
H, Bruzzese FJ, Bump NJ, Soucy TA, Milhollen MA, Yang X, Burkhardt
AL, et al: Substrate-assisted inhibition of ubiquitin-like
protein-activating enzymes: The NEDD8 E1 inhibitor MLN4924 forms a
NEDD8-AMP mimetic in situ. Mol Cell. 37:102–111. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liao H, Liu XJ, Blank JL, Bouck DC,
Bernard H, Garcia K and Lightcap ES: Quantitative proteomic
analysis of cellular protein modulation upon inhibition of the
NEDD8-activating enzyme by MLN4924. Mol Cell Proteomics.
10:M111.0091832011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bennett EJ, Rush J, Gygi SP and Harper JW:
Dynamics of cullin-RING ubiquitin ligase network revealed by
systematic quantitative proteomics. Cell. 143:951–965. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Milhollen MA, Traore T, Adams-Duffy J,
Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey JJ, Koenig E,
Langston SP, et al: MLN4924, a NEDD8-activating enzyme inhibitor,
is active in diffuse large B-cell lymphoma models: Rationale for
treatment of NF-{kappa}B-dependent lymphoma. Blood. 116:1515–1523.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jia L, Li H and Sun Y: Induction of
p21-dependent senescence by an NAE inhibitor, MLN4924, as a
mechanism of growth suppression. Neoplasia. 13:561–569. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Swords RT, Kelly KR, Smith PG, Garnsey JJ,
Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M,
Nawrocki ST, et al: Inhibition of NEDD8-activating enzyme: A novel
approach for the treatment of acute myeloid leukemia. Blood.
115:3796–3800. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin JJ, Milhollen MA, Smith PG, Narayanan
U and Dutta A: NEDD8-targeting drug MLN4924 elicits DNA
rereplication by stabilizing Cdt1 in S phase, triggering checkpoint
activation, apoptosis, and senescence in cancer cells. Cancer Res.
70:10310–10320. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Milhollen MA, Narayanan U, Soucy TA, Veiby
PO, Smith PG and Amidon B: Inhibition of NEDD8-activating enzyme
induces rereplication and apoptosis in human tumor cells consistent
with deregulating CDT1 turnover. Cancer Res. 71:3042–3051. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wei D, Li H, Yu J, Sebolt JT, Zhao L,
Lawrence TS, Smith PG, Morgan MA and Sun Y: Radiosensitization of
human pancreatic cancer cells by MLN4924, an investigational
NEDD8-activating enzyme inhibitor. Cancer Res. 72:282–293. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D,
Pan Y, Ding C, Qian J, Wu L, et al: The Nedd8-activating enzyme
inhibitor MLN4924 induces autophagy and apoptosis to suppress liver
cancer cell growth. Cancer Res. 72:3360–3371. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Woynarowski JM, Faivre S, Herzig MC,
Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A,
Varchenko M and Juniewicz PE: Oxaliplatin-induced damage of
cellular DNA. Mol Pharmacol. 58:920–927. 2000.PubMed/NCBI
|
|
25
|
Nawrocki ST, Kelly KR, Smith PG, Espitia
CM, Possemato A, Beausoleil SA, Milhollen M, Blakemore S, Thomas M,
Berger A and Carew JS: Disrupting protein NEDDylation with MLN4924
is a novel strategy to target cisplatin resistance in ovarian
cancer. Clin Cancer Res. 19:3577–3590. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rogakou EP, Nieves-Neira W, Boon C,
Pommier Y and Bonner WM: Initiation of DNA fragmentation during
apoptosis induces phosphorylation of H2AX histone at serine 139. J
Biol Chem. 275:9390–9395. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matsuoka S, Rotman G, Ogawa A, Shiloh Y,
Tamai K and Elledge SJ: Ataxia telangiectasia-mutated
phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA.
97:10389–10394. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bunz F, Dutriaux A, Lengauer C, Waldman T,
Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B:
Requirement for p53 and p21 to sustain G2 arrest after DNA damage.
Science. 282:1497–1501. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hirao A, Kong YY, Matsuoka S, Wakeham A,
Ruland J, Yoshida H, Liu D, Elledge SJ and Mak TW: DNA
damage-induced activation of p53 by the checkpoint kinase Chk2.
Science. 287:1824–1827. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rainey MD, Black EJ, Zachos G and
Gillespie DA: Chk2 is required for optimal mitotic delay in
response to irradiation-induced DNA damage incurred in G2 phase.
Oncogene. 27:896–906. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kee Y, Huang M, Chang S, Moreau LA, Park
E, Smith PG and D'Andrea AD: Inhibition of the Nedd8 system
sensitizes cells to DNA interstrand cross-linking agents. Mol
Cancer Res. 10:369–377. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fink D, Nebel S, Aebi S, Zheng H, Cenni B,
Nehmé A, Christen RD and Howell SB: The role of DNA mismatch repair
in platinum drug resistance. Cancer Res. 56:4881–4886.
1996.PubMed/NCBI
|
